Longitudinal Magnetic Resonance Imaging Study of Hemodynamic Changes in the Third Trimester in Fetuses With Major Congenital Heart Defects and Healthy Fetuses.
Signe G Hellmuth, Ditte S Jørgensen, Alan Wright, Cathrine Vedel, Ann Tabor, Olav B Petersen, Niels Vejlstrup
{"title":"Longitudinal Magnetic Resonance Imaging Study of Hemodynamic Changes in the Third Trimester in Fetuses With Major Congenital Heart Defects and Healthy Fetuses.","authors":"Signe G Hellmuth, Ditte S Jørgensen, Alan Wright, Cathrine Vedel, Ann Tabor, Olav B Petersen, Niels Vejlstrup","doi":"10.1002/pd.6893","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To assess hemodynamic changes in the third trimester by magnetic resonance imaging (MRI) in fetuses with major congenital heart defects (CHD).</p><p><strong>Methods: </strong>Twenty fetuses with CHD and 23 healthy controls had consecutive MRI at 28, 32, and 38 weeks of gestation. Blood flow in the ascending aorta, main pulmonary artery, and umbilical vein was measured using phase contrast MRI and indexed to estimated fetal weight. Mixed effects models assessed weight-indexed changes over time and between groups. CHD cases were further classified into left-sided defects, right-sided defects, or transposed great arteries for subgroup analysis.</p><p><strong>Results: </strong>Combined ventricular output (CVO) decreased by 1.7% per week (95% CI 0.7%-2.7%) from 28 to 38 weeks in both fetuses with CHD and controls, with no difference between groups (p = 0.3). Umbilical vein (UV) flow decreased by 2.5% per week (95% CI 1.5%-3.5%) with no difference between groups (p = 0.7). CVO was correlated with UV flow (r = 0.6, 95% CI 0.4-0.7). The aortic-to-pulmonary flow ratio remained constant in all subgroups. Left- and right-sided defects were associated with increased flow across the contralateral side.</p><p><strong>Conclusion: </strong>CVO decreased similarly in fetuses with CHD and controls during the third trimester, associated with reduced UV flow, reflecting a more efficient placenta toward term.</p>","PeriodicalId":20387,"journal":{"name":"Prenatal Diagnosis","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prenatal Diagnosis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pd.6893","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: To assess hemodynamic changes in the third trimester by magnetic resonance imaging (MRI) in fetuses with major congenital heart defects (CHD).
Methods: Twenty fetuses with CHD and 23 healthy controls had consecutive MRI at 28, 32, and 38 weeks of gestation. Blood flow in the ascending aorta, main pulmonary artery, and umbilical vein was measured using phase contrast MRI and indexed to estimated fetal weight. Mixed effects models assessed weight-indexed changes over time and between groups. CHD cases were further classified into left-sided defects, right-sided defects, or transposed great arteries for subgroup analysis.
Results: Combined ventricular output (CVO) decreased by 1.7% per week (95% CI 0.7%-2.7%) from 28 to 38 weeks in both fetuses with CHD and controls, with no difference between groups (p = 0.3). Umbilical vein (UV) flow decreased by 2.5% per week (95% CI 1.5%-3.5%) with no difference between groups (p = 0.7). CVO was correlated with UV flow (r = 0.6, 95% CI 0.4-0.7). The aortic-to-pulmonary flow ratio remained constant in all subgroups. Left- and right-sided defects were associated with increased flow across the contralateral side.
Conclusion: CVO decreased similarly in fetuses with CHD and controls during the third trimester, associated with reduced UV flow, reflecting a more efficient placenta toward term.
期刊介绍:
Prenatal Diagnosis welcomes submissions in all aspects of prenatal diagnosis with a particular focus on areas in which molecular biology and genetics interface with prenatal care and therapy, encompassing: all aspects of fetal imaging, including sonography and magnetic resonance imaging; prenatal cytogenetics, including molecular studies and array CGH; prenatal screening studies; fetal cells and cell-free nucleic acids in maternal blood and other fluids; preimplantation genetic diagnosis (PGD); prenatal diagnosis of single gene disorders, including metabolic disorders; fetal therapy; fetal and placental development and pathology; development and evaluation of laboratory services for prenatal diagnosis; psychosocial, legal, ethical and economic aspects of prenatal diagnosis; prenatal genetic counseling